AstraZeneca's monoclonal antibody combination tixagevimab-cilgavimab (Evusheld) reduced the risk of symptomatic COVID-19 infection by 83% over placebo at a median follow-up of 6 months, finds a phase 3 randomized clinical trial published yesterday in the New England Journal of Medicine. It has emergency use authorization and is meant for immunocompromised individuals. I am on Ocrevus (which reduces antibodies serum effectiveness) and I am going to test my antibody levels approx. 5 months after Evusheld infusion to see if I am in normal range. Very limited supply in NA. Just google it.